Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2009

Open Access 01-12-2009 | Short communication

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

Authors: Edurne San José-Enériz, José Román-Gómez, Antonio Jiménez-Velasco, Leire Garate, Vanesa Martin, Lucia Cordeu, Amaia Vilas-Zornoza, Paula Rodríguez-Otero, María José Calasanz, Felipe Prósper, Xabier Agirre

Published in: Molecular Cancer | Issue 1/2009

Login to get access

Abstract

The development of Imatinib Mesylate (IM), the first specific inhibitor of BCR-ABL1, has had a major impact in patients with Chronic Myeloid Leukemia (CML), establishing IM as the standard therapy for CML. Despite the clinical success obtained with the use of IM, primary resistance to IM and molecular evidence of persistent disease has been observed in 20-25% of IM treated patients. The existence of second generation TK inhibitors, which are effective in patients with IM resistance, makes identification of predictors of resistance to IM an important goal in CML. In this study, we have identified a group of 19 miRNAs that may predict clinical resistance to IM in patients with newly diagnosed CML.
Appendix
Available only for authorised users
Literature
1.
Apperley JF: Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncology. 2007, 8: 1018-29. 10.1016/S1470-2045(07)70342-XCrossRefPubMed
2.
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine. 2006, 355: 2408-17. 10.1056/NEJMoa062867CrossRefPubMed
3.
Agirre X, Jiménez-Velasco A, San José-Enériz E, Garate L, Bandrés E, Cordeu L, Aparicio O, Saez B, Navarro G, Vilas-Zornoza A, Pérez-Roger I, García-Foncillas J, Torres A, Heiniger A, Calasanz MJ, Fortes P, Román-Gómez J, Prósper F: Hematopoietic tissue-specific hsa-miR-10a is down regulated in Chronic Myeloid Leukemia. Molecular Cancer Research. 2008, 6: 1830-40. 10.1158/1541-7786.MCR-08-0167CrossRefPubMed
4.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-8. 10.1038/nature03702CrossRefPubMed
5.
Ramkissoon SH, Mainwaring LA, Ogasawara Y, Keyvanfar K, McCoy JP, Sloand EM, Kajigaya S, Young NS: Hematopoietic-specific microRNA expression in human cells. Leukemia Research. 2006, 30: 643-647. 10.1016/j.leukres.2005.09.001CrossRefPubMed
6.
Venturini L, Battmer K, Castoldi M, Schultheis B, Hochhaus A, Muckenthaler MU, Ganser A, Eder M, Scherr M: Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells. Blood. 2007, 109: 4399-405. 10.1182/blood-2006-09-045104CrossRefPubMed
7.
Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology. 2008, 26: 5078-87. 10.1200/JCO.2008.17.5554PubMedCentralCrossRefPubMed
8.
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun S, Hong L, Liu J, Fan D: miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International Journal of Cancer. 2008, 123: 372-9. 10.1002/ijc.23501. 10.1002/ijc.23501CrossRef
9.
Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM: Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol. 2008, 76: 582-8. 10.1016/j.bcp.2008.06.007PubMedCentralCrossRefPubMed
10.
Chung YJ, Kim TM, Kim DW, Namkoong H, Kim HK, Ha SA, Kim S, Shin SM, Kim JH, Lee YJ, Kang HM, Kim JW: Gene expression signatures associated with the resistance to imatinib. Leukemia. 2006, 20: 1542-50. 10.1038/sj.leu.2404310CrossRefPubMed
11.
Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS, Kim DW, Kang CD, Kim SH: Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. J Pharmacol Exp Ther. 2007, 322: 1084-92. 10.1124/jpet.107.124461CrossRefPubMed
Metadata
Title
MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations
Authors
Edurne San José-Enériz
José Román-Gómez
Antonio Jiménez-Velasco
Leire Garate
Vanesa Martin
Lucia Cordeu
Amaia Vilas-Zornoza
Paula Rodríguez-Otero
María José Calasanz
Felipe Prósper
Xabier Agirre
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-8-69

Other articles of this Issue 1/2009

Molecular Cancer 1/2009 Go to the issue

Research

δ-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles

Research

Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC

Research

PIK3CA alterations in Middle Eastern ovarian cancers

Research

Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth

Research

Dual effects of TGF-β on ERα-mediated estrogenic transcriptional activity in breast cancer

Research

Mitomycin C induces bystander killing in homogeneous and heterogeneous hepatoma cellular models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits